ID: ALA5218533

Max Phase: Preclinical

Molecular Formula: C19H16N4O2

Molecular Weight: 332.36

Associated Items:

Representations

Canonical SMILES:  COc1ccc(-c2cnc3c(c2)nnn3-c2ccccc2)cc1OC

Standard InChI:  InChI=1S/C19H16N4O2/c1-24-17-9-8-13(11-18(17)25-2)14-10-16-19(20-12-14)23(22-21-16)15-6-4-3-5-7-15/h3-12H,1-2H3

Standard InChI Key:  QFWTYDYTUMGDGW-UHFFFAOYSA-N

Associated Targets(Human)

Serine/threonine-protein kinase GAK 1150 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 332.36Molecular Weight (Monoisotopic): 332.1273AlogP: 3.50#Rotatable Bonds: 4
Polar Surface Area: 62.06Molecular Species: NEUTRALHBA: 6HBD: 0
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 3.56CX LogD: 3.56
Aromatic Rings: 4Heavy Atoms: 25QED Weighted: 0.57Np Likeness Score: -1.31

References

1. Callis TB, Garrett TR, Montgomery AP, Danon JJ, Kassiou M..  (2022)  Recent Scaffold Hopping Applications in Central Nervous System Drug Discovery.,  65  (20.0): [PMID:36206553] [10.1021/acs.jmedchem.2c00969]

Source